These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1008908)

  • 1. Effects of clofibrate treatment on arginine-induced insulin secretion in endogenous hypertriglyceridemia.
    Fedele D; Tiengo A; Muggeo M; Nosadini R; Crepaldi G
    Atherosclerosis; 1976; 25(2-3):191-8. PubMed ID: 1008908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
    Tiengo A; Muggeo M; Assan R; Fedele D; Crepaldi G
    Metabolism; 1975 Aug; 24(8):901-14. PubMed ID: 1143089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
    Schwandt P; Weisweiler P; Neureuther G; Wilkening J
    MMW Munch Med Wochenschr; 1976 Mar; 118(12):351-4. PubMed ID: 177863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of obesity on the relationship between insulin and triglyceride levels in endogenous hypertriglyceridemia.
    Bagdade JD; Bierman EL; Porte D
    Diabetes; 1971 Oct; 20(10):664-72. PubMed ID: 5110698
    [No Abstract]   [Full Text] [Related]  

  • 5. The influence of plasma triglycerides on human growth hormone response to arginine and insulin: a study in hyperlipemics and normal subjects.
    Muggeo M; Tiengo A; Fedele D; Crepaldi G
    Horm Metab Res; 1975 Sep; 7(5):367-74. PubMed ID: 1183914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of clofibrate on arginine-induced insulin and glucagon secretion.
    Eaton RP
    Metabolism; 1973 Jun; 22(6):763-7. PubMed ID: 4350845
    [No Abstract]   [Full Text] [Related]  

  • 7. Growth hormone secretion in primary endogenous hypertriglyceridemia.
    Muggeo M; Fedele D; Tiengo A; Crepaldi G
    Horm Metab Res; 1973 May; 5(3):224-5. PubMed ID: 4714551
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
    Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
    Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
    Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
    Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
    Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
    Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of clofibrate on arginine-stimulated glucagon and insulin secretion in man.
    Eaton RP; Schade DS
    Metabolism; 1974 May; 23(5):445-54. PubMed ID: 4825301
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
    Enger SC; Johnsen V; Samuelsen A; Laws EA
    Acta Med Scand; 1977; 201(6):563-6. PubMed ID: 327758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.
    Wolfe BM; Kane JP; Havel RJ; Brewster HP
    J Clin Invest; 1973 Sep; 52(9):2146-59. PubMed ID: 4353773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of increased plasma non-esterified fatty acids (NEFAs) on arginine-stimulated insulin secretion in obese humans.
    Carpentier A; Giacca A; Lewis GF
    Diabetologia; 2001 Nov; 44(11):1989-97. PubMed ID: 11719829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between insulin secretion and triglyceride concentration in endogenous lipemia.
    Eaton BP; Nye WH
    J Lab Clin Med; 1973 May; 81(5):682-95. PubMed ID: 4349136
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
    Feldman EB; Gluck FB; Carter AC
    J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperlipiemia and its therapy by clofibrate].
    Nakano M; Nakamura Y
    Iryo; 1969 Dec; 23(12):1473-8. PubMed ID: 5381198
    [No Abstract]   [Full Text] [Related]  

  • 18. Clofibrate-induced changes in glucagon and insulin secretion in patients with angiographically documented coronary artery disease.
    Eaton RP; Schade DS; Lueker R
    Am J Clin Nutr; 1977 Dec; 30(12):2068-77. PubMed ID: 930877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen.
    Lithell H; Boberg J; Hedstrand H; Hellsing K; Ljunghall S; Vessby B
    Eur J Clin Pharmacol; 1977 Aug; 12(1):51-7. PubMed ID: 332503
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic effects of clofibrate in insulin-dependent ketosis-prone diabetic man.
    Schade DS; Eaton RP; George S; Conway M; Kaminsky N; Sivinski J
    Metabolism; 1978 Apr; 27(4):461-8. PubMed ID: 416322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.